Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
Status:
RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University